Current Concepts in the Diagnosis and Management of Adult Primary Immune Thrombocytopenia: Our Personal View

Author:

González-López Tomás José1ORCID,Newland Adrian2,Provan Drew2

Affiliation:

1. Hematology Department, Hospital Universitario de Burgos, 09006 Burgos, Spain

2. Academic Haematology Unit, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London E1 2BB, UK

Abstract

Primary immune thrombocytopenia (ITP) is an acquired blood disorder that causes a reduction in circulating platelets with the potential for bleeding. The incidence of ITP is slightly higher in adults and affects more women than men until 60 years, when males are more affected. Despite advances in basic science, primary ITP remains a diagnosis of exclusion. The disease is heterogeneous in its clinical behavior and response to treatment. This reflects the complex underlying pathophysiology, which remains ill-understood. Platelet destruction plays a role in thrombocytopenia, but underproduction is also a major contributing factor. Active ITP is a proinflammatory autoimmune disease involving abnormalities within the T and B regulatory cell compartments, along with several other immunological abnormalities. Over the last several years, there has been a shift from using immunosuppressive therapies for ITP towards approved treatments, such as thrombopoietin receptor agonists. The recent COVID-19 pandemic has hastened this management shift, with thrombopoietin receptor agonists becoming the predominant second-line treatment. A greater understanding of the underlying mechanisms has led to the development of several targeted therapies, some of which have been approved, with others still undergoing clinical development. Here we outline our view of the disease, including our opinion about the major diagnostic and therapeutic challenges. We also discuss our management of adult ITP and our placement of the various available therapies.

Publisher

MDPI AG

Subject

General Medicine

Reference59 articles.

1. Immune thrombocytopenia;Kistangari;Hematol./Oncol. Clin. N. Am.,2013

2. Bleeding complications in immune thrombocytopenia;Arnold;Hematol. Am. Soc. Hematol. Educ. Program,2015

3. Pathogenesis of immune thrombocytopenia;Audia;Autoimmun. Rev.,2017

4. The immune thrombocytopenia syndrome: A disorder of diverse pathogenesis and clinical presentation;Cines;Hematol./Oncol. Clin. N. Am.,2009

5. The incidence of idiopathic thrombocytopenic purpura in adults increases with age;Frederiksen;Blood,1999

Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3